Viking Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Viking Therapeutics, Inc. (VKTX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$29.63 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-09
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$29.63M, a 1553.02% decline year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$4.40M, a 403.72% decline year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $1.39M, a 215.59% increase year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$765.06K.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$1.73M, a 157.09% decline from fiscal 2016.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $3.03M.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$13.47M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | -$29.63M 10-Q · filed 2018-05-09 | -$34.02M derived: sum of 2 quarters · filed 2018-05-09 | -$32.63M derived: sum of 3 quarters · filed 2018-05-09 | -$33.40M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-12-31 | -$4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$3.00M derived: sum of 2 quarters · filed 2018-03-07 | -$3.77M derived: sum of 3 quarters · filed 2018-03-07 | -$1.73M 10-K · filed 2018-03-07 | |
| 2017-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $626.77K derived: sum of 2 quarters · filed 2017-11-08 | $2.67M 10-Q · filed 2017-11-08 | $4.11M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-06-30 | -$765.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.27M 10-Q · filed 2017-08-09 | $2.72M derived: sum of 3 quarters · filed 2018-05-09 | $3.16M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-03-31 | $2.04M 10-Q · filed 2018-05-09 | $2.04M 10-Q · filed 2017-05-10 | $3.49M derived: sum of 2 quarters · filed 2018-05-09 | $3.93M derived: sum of 3 quarters · filed 2018-05-09 | -$903.88K derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $1.89M derived: sum of 2 quarters · filed 2018-03-07 | -$2.94M derived: sum of 3 quarters · filed 2018-03-07 | $3.03M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $441.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$4.39M derived: sum of 2 quarters · filed 2017-11-08 | $1.58M 10-Q · filed 2017-11-08 | $3.54M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2016-06-30 | -$4.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.14M 10-Q · filed 2017-08-09 | $3.10M derived: sum of 3 quarters · filed 2017-08-09 | -$154.45K derived: sum of 4 quarters · filed 2017-08-09 | |
| 2016-03-31 | $5.97M 10-Q · filed 2017-05-10 | $7.93M derived: sum of 2 quarters · filed 2017-05-10 | $4.68M derived: sum of 3 quarters · filed 2017-05-10 | ||
| 2015-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | -$1.30M derived: sum of 2 quarters · filed 2017-03-21 | -$13.47M 10-K · filed 2017-03-21 | ||
| 2015-09-30 | -$3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$15.43M 10-Q · filed 2016-11-10 | |||
| 2015-06-30 | -$12.17M 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |